ALERGOLOGÍA PARA MÉDICOS Y PACIENTES 2021

Síndrome hipereosinofílico (Dra. Luisa Holguín-año 2016)

Fisiopatología de la dermatitis de contacto (Dr. Steven Fuentes Abreu)

Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Authors: Devillier P1, Humbert M2, Boye A3, Zachgo W4, Jacques L5, Nunn C6, West S7, Nicholls A8, Antoun Z9, Spinu L10, Grouin JM11. 1 UPRES EA220, Airway Disease Department, Foch Hospital, University Paris-Saclay, Suresnes, France. Electronic address: P.DEVILLIER@hopital-foch.org. 2 Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre; and Service de Pneumologie, Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France. Electronic address: mjc.humbert@gmail.com. 3 Nouvelles Cliniques Nantaises, Nantes, France. Electronic address: a.boye@clinouest.fr. 4 Lungenzentrum Geesthacht, Geesthacht, Germany. Electronic address: wz@mikloweit-zachgo.de. 5 GlaxoSmithKline, Respiratory Medicines De

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria Authors:  Kaplan AP1, Giménez-Arnau AM2, Saini SS3. 1 Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. 2 Department of Dermatology, Hospital del Mar, Institut Mar D'Investigacions Mediques, Universitat Autònoma, Barcelona, Spain. 3 Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. Abstract: The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently unders

Clinical Approach to the Therapy of Asthma-COPD Overlap. Authors:  Maselli DJ1, Hardin M2, Christenson SA3, Hanania NA4, Hersh CP5, Adams SG6, Anzueto A6, Peters JI6, Han MK7, Martinez FJ8. 1 Division of Pulmonary Diseases & Critical Care Medicine, Department of Medicine, University of Texas Health at San Antonio, San Antonio, TX. Electronic address: MaselliCacer@uthscsa.edu. 2 AstraZeneca LLC, Waltham, MA. 3 Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA. 4 Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX. 5 Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 6 Division of Pulmonary Diseases & Critical Care Medicine, Department of Medicine, University of Texas Health at San Antonio, San Antonio, TX; South Texas Veterans Health Care

Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial. Authors:  Sánchez-Armendáriz K1, García-Gil A1, Romero CA2, Contreras-Ruiz J1, Karam-Orante M1, Balcazar-Antonio D3, Domínguez-Cherit J4. 1 Department of Dermatology, General Hospital "Dr. Manuel Gea González", Mexico city, Mexico. 2 Research Scientist-Instructor Henry Ford Hospital, Detroit, MI, USA. 3 Clinical Laboratory of the National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico city, Mexico. 4 Department of Dermatology, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico city, Mexico. Abstract:  BACKGROUND: Vitamin D has immunomodulatory effects both in the innate and adaptive immune systems, and there is growing scientific evidence demonstrating its relevance in inflammatory processes such as AD. HYPOTHESIS: If vitamin D3 promotes the skin immune system, then it should improve the response to tr

FISIOPATOLOGÍA DE LOS ÁCAROS (DR JAIME SOSA)

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. Authors: Castro M1, Corren J1, Pavord ID1, Maspero J1, Wenzel S1, Rabe KF1, Busse WW1, Ford L1, Sher L1, FitzGerald JM1, Katelaris C1, Tohda Y1, Zhang B1, Staudinger H1, Pirozzi G1, Amin N1, Ruddy M1, Akinlade B1, Khan A1, Chao J1, Martincova R1, Graham NMH1, Hamilton JD1, Swanson BN1, Stahl N1, Yancopoulos GD1, Teper A1. 1 From the Washington University School of Medicine, St. Louis (M.C.); David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J. Corren), and Peninsula Research Associates, Rolling Hills Estates (L.S.) - both in California; Oxford Respiratory National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom (I.D.P.); Fundación CIDEA (Centro de Investigación de Enfermedades Alérgicas y Respiratorias), Buenos Aires (J.M.); the University of Pittsburgh Asthma Institute, University of Pittsburgh, Pittsburgh (S.W

Urticaria in children and adolescents: An updated review of the pathogenesis and management. Authors: Kudryavtseva AV1, Neskorodova KA1, Staubach P2. 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia. 2 Department of Dermatology, University Medical Center, Mainz, Germany. Abstract: The present survey represents the latest data on diagnosis and management of childhood urticaria. It has been observed that urticaria occurs less often in children than adults, with symptoms rarely lasting for over 6 weeks. Triggers or aggravating factors can be found only in 21%-55% of cases. Finding autoantibodies in children does not impact a disease prognosis, unlike in adult patients, where the presence of autoantibodies is associated with a more prolonged run of the disease, a more severe prognosis and more intensive treatment methods. The incidence of food allergy equals to 8%-10% of cases. The incidence of Helicobacter Pylori infection in children is lower than that in

Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. Authors:   Workman AD1, Kohanski MA1, Cohen NA2. 1 Department of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA. 2 Department of Otorhinolaryngology-Head and Neck Surgery, Division of Rhinology, University of Pennsylvania, Perelman School of Medicine, 3400 Spruce Street, Philadelphia, PA 19104, USA; Philadelphia Veterans Affairs Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA; Monell Chemical Senses Center, 3500 Market Street, Philadelphia, PA 19104, USA. Electronic address: Noam.Cohen@uphs.upenn.edu. Abstract: Chronic rhinosinusitis is a complex disease that exists along the inflammatory spectrum between types 1 and 2 inflammation. The classic phenotypic differentiation of chronic rhinosinusitis based on the presence or absence of inflammatory polyps remains one of the best diff

Yogurt is tolerated by the majority of children with IgE-mediated cow's milk allergy Authors:  Monaco S1, Russo G1, Romano A1, Liotti L2, Verga MC3, Miceli Sopo S4. 1 Allergy Unit, Pediatrics Area, Department of Woman and Child Health, Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre Hearth, Rome, Italy. 2 Allergy Unit, Pediatric Clinic, Civil Hospital, Senigallia, Italy. 3 Primary Care Pediatrics, ASL Salerno, Italy. 4 Allergy Unit, Pediatrics Area, Department of Woman and Child Health, Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre Hearth, Rome, Italy. Electronic address: stefano.micelisopo@unicatt.it. Abstract: BACKGROUND: Children with IgE-mediated cow's milk allergy (IgE-CMA) with gastrointestinal symptoms tolerate yogurt at 100%. Yogurt tolerance in children with IgE-CMA with urticaria and anaphylaxis was 7%. METHODS: We enrolled children with IgE-CMA with cutaneous, respiratory, gastrointes

Fisiopatología de la anafilaxia (Dr Steven Fuentes)

Fisiopatología de la urticaria crónica espontánea (Dra Gloria Gil) Generalidades de la rinitis alérgica local (Dr Luis Santamaría)

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. Authors: Castro M1, Corren J1, Pavord ID1, Maspero J1, Wenzel S1, Rabe KF1, Busse WW1, Ford L1, Sher L1, FitzGerald JM1, Katelaris C1, Tohda Y1, Zhang B1, Staudinger H1, Pirozzi G1, Amin N1, Ruddy M1, Akinlade B1, Khan A1, Chao J1, Martincova R1, Graham NMH1, Hamilton JD1, Swanson BN1, Stahl N1, Yancopoulos GD1, Teper A1. 1 From the Washington University School of Medicine, St. Louis (M.C.); David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles (J. Corren), and Peninsula Research Associates, Rolling Hills Estates (L.S.) - both in California; Oxford Respiratory National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom (I.D.P.); Fundación CIDEA (Centro de Investigación de Enfermedades Alérgicas y Respiratorias), Buenos Aires (J.M.); the University of Pittsburgh Asthma Institute, University of Pittsburgh, Pittsburgh (S.W

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. Authors:  Nair P1, Wenzel S1, Rabe KF1, Bourdin A1, Lugogo NL1, Kuna P1, Barker P1, Sproule S1, Ponnarambil S1, Goldman M1; ZONDA Trial Investigators. 1 From McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada (P.N.); University of Pittsburgh, Pittsburgh (S.W.); LungenClinic Grosshansdorf and Department of Medicine, Airway Research Center North of the German Center for Lung Research, Christian Albrechts University, Kiel, Germany (K.F.R.); Département de Pneumologie et Addictologie, PhyMedExp, University of Montpellier, INSERM Unité 1046, Centre National de la Recherche Scientifique Unité Mixte de Recherche 9214, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France (A.B.); Duke University Medical Center, Durham, NC (N.L.L.); Barlicki University Hospital, Medical University of Lodz, Lodz, Poland (P.K.); AstraZeneca, Gaithersburg, MD (P.B., S.S.,

Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab. Authors: Spertino J1, Curto Barredo L2, Rozas Muñoz E3, Figueras Nart I4, Gimenez Arnau A2, Serra Baldrich E3, Bonfill-Ortí M4, Expósito-Serrano V5, Guilabert A6, Melé Ninot G7, Villar Buil M8, Garcias Ladaria J9, García Navarro X10, Vilavella M11, Bielsa Marsol I12, Aparicio Ortiz G13, Baliu Piqué C14, Álvarez Abella A15, Lamas Domenech N16, Mascaró JM17, Gómez S17, Torné Gutiérrez JI18, Vicente Villa A19, Gimenez Arnau A2. 1 Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: jspertino@outlook.com. 2 Parc de Salut Mar-Hospital del Mar, Barcelona, España. 3 Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. 4 Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, España. 5 Corporació Sanitària Parc Taulí, Sabadell, Barcelona, España. 6 Hospital General de Granollers, Granollers, Barcelona, España. 7

Non-atopic rhinitis at age 6 is associated with subsequent development of asthma. Authors:  Carr TF1, Stern DA1, Halonen M1, Wright AL1, Martinez FD1. 1 Asthma and Airway Disease Research Center, University of Arizona, Tucson, Arizona. Abstract: BACKGROUND: It has been postulated that the association between allergic rhinitis and asthma is attributable to the progressive clinical expression of respiratory inflammation during childhood. The role of non-allergic rhinitis in early life in relation to subsequent asthma has not been extensively explored. OBJECTIVE: We sought to determine whether rhinitis in early life was associated with risk of asthma development into adulthood, and whether this relationship is independent of allergic sensitization. METHODS: Participants were identified from the Tucson Children's Respiratory Study, a non-selected birth cohort. Allergy skin prick testing was performed at age 6 years using house dust mix, Bermuda, mesquite, olive, mulbe

Fisiopatología de la alergia a medicamentos (Dra. Catalina López)

An in-depth characterization of a large cohort of adult patients with eosinophilic esophagitis Authors:  Leigh LY1, Spergel JM2. 1 Section of Allergy and Immunology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. Electronic address: spergel@email.chop.edu. 2 Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Abstract: BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic, allergic, immune-mediated disease associated with increased risk of comorbid atopic conditions. OBJECTIVE: To perform an in-depth characterization of a large cohort of manually verified adult patients with EoE, including evaluation of less studied associations, such as pollen food allergy syndrome, anaphylaxis, autoimmunity, and

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Authors: de Bruin-Weller M1, Thaçi D2, Smith CH3, Reich K4, Cork MJ5, Radin A6, Zhang Q7, Akinlade B6, Gadkari A6, Eckert L8, Hultsch T9, Chen Z6, Pirozzi G10, Graham NMH6, Shumel B6. 1 University Medical Center Utrecht, Utrecht, the Netherlands. 2 University of Lübeck, Lübeck, Germany. 3 St. John's Institute of Dermatology, London, U.K. 4 Dermatologikum and TFS Research Institute, Hamburg, Germany. 5 Sheffield Dermatology Research, The University of Sheffield, Sheffield, U.K. 6 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A. 7 Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, U.S.A. 8 Sanofi, Chilly-Mazarin, France. 9 Sanofi, Cambridge, MA, U.S.A. 10 Sanofi, Bridgewater, NJ, U.S.A

New biologics in the treatment of urticaria. Authors: Kocatürk E1, Zuberbier T2. 1 Department of Dermatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 2 Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany. Abstract:  PURPOSE OF REVIEW: Symptomatic management of chronic spontaneous urticaria (CSU) basically depends on second-generation H1 antihistamines and omalizumab. Omalizumab is a game changer in the management, but still there is a need for new targets and new biologics targeting new pathways in the treatment which will provide long-lasting remission, which will be given orally and which will be cheaper. This review will focus on new biologics that are underway of production or are already under use for different disorders but could be beneficial for the treatment of Chronic urticaria. RECENT FINDINGS: In this review, the treatment targets are classified according to the cells which are involved in the pathogenesi

Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments. Authors: Jartti T1, Smits HH2, Bønnelykke K3, Bircan O4, Elenius V1, Konradsen JR5,6,7, Maggina P8, Makrinioti H9, Stokholm J3, Hedlin G5,6, Papadopoulos N8,10, Ruszczynski M11, Ryczaj K12, Schaub B13, Schwarze J14, Skevaki C15,16, Stenberg-Hammar K5,6, Feleszko W12; EAACI Task Force on Clinical Practice Recommendations on Preschool Wheeze. 1 Department of Pediatrics, Turku University Hospital and University of Turku, Turku, Finland. 2 Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands. 3 COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 4 Department of Pediatric Allergy, Istanbul Medeniyet University Göztepe Training and Research Hospital, Istanbul, Turkey. 5 Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden. 6 Departme

The basophil activation test differentiates between patients with alpha-gal syndrome and asymptomatic alpha-gal sensitization. Authors: Mehlich J1, Fischer J2, Hilger C3, Swiontek K3, Morisset M4, Codreanu-Morel F4, Schiener M5, Blank S5, Ollert M3, Darsow U1, Biedermann T1, Eberlein B6. 1 Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany. 2 Department of Dermatology, Faculty of Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany. 3 Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg. 4 Immunology-Allergology Department, Luxembourg Hospital, Luxembourg-Ville, Luxembourg. 5 Center of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Munich, Germany. 6 Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany. Electronic address: bernadette.eberlein@tum.de. Abstract: BACKGROUND: Ga